conclusions compared with monotherapy, adding ribavirin to treatment is more effective in removing hepatitis c virus from the bloodstream in patients with thalassemia, it is also more effective in reducing the relapse rate after treatment. except the increase in blood transfusion, there was no significant increase in side effects followed by adding ribavirin. results three randomized clinical t...

conclusions several adverse effects are associated to anti-hcv drugs, hence appropriate skin care management and follow-up are very important. a careful anamnesis before the initiation of triple therapy is necessary to identify previous dermatological diseases that could increase skin adverse effects incidence. case presentation we report a case of a patient who discontinued telaprevir because ...

A 64-year-old woman with hepatitis C was treated using combination therapy with peginterferon α-2a and ribavirin. After 3 months, she presented with raised nodules on her knees and elbows. After 8 months, she developed painful subcutaneous nodules on her forearms. We diagnosed sarcoidosis with both plaques and subcutaneous nodules associated with combination therapy with peginterferon α-2a and ...

INTRODUCTION Dermatological adverse events are an existing concern during treatment of hepatitis C virus infection. Peginterferon/ribavirin treatment is associated with well-characterized dermatological lesions tending towards a uniform entity of dermatitis. New telaprevir- or boceprevir-based triple-therapy has led to significant improvements in sustained virological response rates, although a...

BACKGROUND We describe the first case of systemic cat scratch disease in a patient receiving peginterferon alpha-2a and ribavirin for treatment of hepatitis C. Cases of adult systemic CSD are extremely infrequent and immunomodulatory treatment for hepatitis C has been associated with aberrant host responses to common pathogens. CASE PRESENTATION A 52 year old man being treated for hepatitis C...

background most thalassemic patients with chronic hepatitis c virus (hcv) infection do not respond to therapy with pegylated interferon (peg-ifn) plus ribavirin (rbv) due to hepatic siderosis and rbv dose reduction caused by rbv-induced anemia. objectives in the present study, we recruited hcv genotype 1-infected thalassemic patients who had relapsed after a 48-week treatment with peg-ifn plus ...

Two direct-acting antivirals (DAAs) against hepatitis C virus (HCV): telaprevir and boceprevir, are now available in combination with peginterferon plus ribavirin for the treatment of chronic hepatitis C infection. Although these drugs are potent inhibitors of HCV replication, they occasionally result in severe adverse events. In the present clinical trials, in their stead, several second-gener...

The first generation protease inhibitors has been the mainstay of hepatitis C treatment for the last couple of years, showing marked improvement in sustained virological response, but also increased side effects. Infection has emerged as a common complication of telaprevir and boceprevir in combination with peginterferon and ribavirin, usually caused by common pathogens. We present the case of ...

In The Lancet Infectious Diseases, Eric Lawitz and colleagues report results from their randomised phase 2 trial, in which they showed a more than 90% cure rate of hepatitis C in patients given a combination of pegylated interferon alfa-2a (peginterferon), ribavirin, and sofosbuvir, a novel nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase. Among the 60 or so drugs under devel...

A new era of therapy for hepatitis C virus (HCV) infection is dawning with the development of two effective HCV protease inhibitors, boceprevir and telaprevir. In this issue of the Journal, the results of two phase 3 trials involving boceprevir, in combination with peginterferon and ribavirin, are presented: the SPRINT-2 (Serine Protease Inhibitor Therapy 2) trial (ClinicalTrials.gov number, NC...